...10...1819202122...304050...


AgeX Therapeutics Announces Drawdown of Second Tranche of Loan Facility from Juvenescence Ltd. – BioSpace

Juvenescence is pleased to continue its commitment to AgeX through this additional drawdown under the loan facility, commented Gregory Bailey, MD, Chairman of AgeX and CEO of Juvenescence. Juvenescence remains committed to funding the future development plans of AgeX through further advancements under the loan facility or otherwise. Since Juvenescences initial investment in AgeX in June 2018, AgeX has been an important element in the Juvenescence mission and strategy. Juvenescence is also investing its time and personnel to support AgeXs business development initiatives which have impressive potential. We look forward to AgeX announcing its plans for 2020 as it pursues tissue regeneration in Reverse Bioengineering, while advancing the development of BAT and VASC 1, the coupling of HLA-G with PureStem-derived cells for transplant therapies, and exploring partnerships with third parties.

This round of funding will allow us to continue to execute on our strategic plan to provide therapies for certain chronic and degenerative diseases through cellular regeneration and replacement, commented AgeXs founder and CEO Michael D. West, PhD.

As announced in the companys news release on August 14, 2019, AgeX has obtained a $2 million credit facility from Juvenescence to finance AgeXs operations and advance its product development programs.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191226005045/en/

See the original post here:

AgeX Therapeutics Announces Drawdown of Second Tranche of Loan Facility from Juvenescence Ltd. - BioSpace

The Next Generation of Biologic Pacemakers? New Discovery in Stem Cells from Fat Creates Another Alternative Treatment – DocWire News

A research team from the University of Houston has found a way to use the stem cells found in fat and guide it to become a pacemaker-like cell, according to a new study.

We are reprogramming the cardiac progenitor cell and guiding it to become a conducting cell of the heart to conduct electrical current, said study co-author Bradley McConnell, associate professor of pharmacology, in a press release

The team, publishing the study in the Journal of Molecular and Cellular Cardiology, worked on converting adipogenic mesenchymal stem cells, which reside within fat cells, into cardia progenitor cells. The ensuing cardiac progenitor cells can be programmed to aid heartbeats as a sinoatrial node (SAN), which is part of the electrical cardiac conduction system.

The researchers used what they called a standard screening strategy to test for reprogramming factors for converting human cardiac progenitor cells into pacemaker-like cells. According to their study results, the authors observed expressions of many pacemaker-specific genes, including CX30.2, KCNN4, HCN4, HCN3, HCN1, and SCN3b. The authors wrote that SHOX2, HCN2, and TBX5 (SHT5) combinations of transcription factors were much better candidate(s) in driving cardiac progenitor cells into pacemaker-like cells than other combinations and single transcription factors.

Results of this study show that the SHT5 combination of transcription factors can reprogram CPCs into Pacemaker-like cells, they wrote in their conclusion. SHT5 may be used as a potential stem cell therapy for sick sinus syndrome (SSS) and for other cardiac conduction diseases.

Continue reading here:

The Next Generation of Biologic Pacemakers? New Discovery in Stem Cells from Fat Creates Another Alternative Treatment - DocWire News

Stem Cell Therapy Market Consumer Outlook 2025 | MEDIPOST Co., Ltd., Osiris Therapeutics, Inc. – Market Research Sheets

Stem Cell Therapy Market: Snapshot

Of late, there has been an increasing awareness regarding the therapeutic potential of stem cells for management of diseases which is boosting the growth of the stem cell therapy market. The development of advanced genome based cell analysis techniques, identification of new stem cell lines, increasing investments in research and development as well as infrastructure development for the processing and banking of stem cell are encouraging the growth of the global stem cell therapy market.

To know Untapped Opportunities in the MarketCLICK HERE NOW

One of the key factors boosting the growth of this market is the limitations of traditional organ transplantation such as the risk of infection, rejection, and immunosuppression risk. Another drawback of conventional organ transplantation is that doctors have to depend on organ donors completely. All these issues can be eliminated, by the application of stem cell therapy. Another factor which is helping the growth in this market is the growing pipeline and development of drugs for emerging applications. Increased research studies aiming to widen the scope of stem cell will also fuel the growth of the market. Scientists are constantly engaged in trying to find out novel methods for creating human stem cells in response to the growing demand for stem cell production to be used for disease management.

It is estimated that the dermatology application will contribute significantly the growth of the global stem cell therapy market. This is because stem cell therapy can help decrease the after effects of general treatments for burns such as infections, scars, and adhesion. The increasing number of patients suffering from diabetes and growing cases of trauma surgery will fuel the adoption of stem cell therapy in the dermatology segment.

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Get Discount on Latest Report @CLICK HERE NOW

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Request TOC of the Reportfor more Industry Insights @CLICK HERE NOW

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

This post was originally published on Market Research Sheets

See the original post here:

Stem Cell Therapy Market Consumer Outlook 2025 | MEDIPOST Co., Ltd., Osiris Therapeutics, Inc. - Market Research Sheets

Updates in the Management of Multiple Myeloma – Pharmacy Times

Multiple Myeloma (MM) is the 14th-most-common cancer, accounting for approximately 1.8% of all cancers and 17.0% of all hematologic malignancies in the United States.1,2 An estimated 32,110 new myeloma cases will be diagnosed in the United States in 2019, with an estimated 12,960 deaths, which represents 2.1% of all cancer-related deaths. MM is most frequently diagnosed in people aged 65 to 74 years, with a median age of 69 years at diagnosis and a median age of 75 years at death.

The National Comprehensive Cancer Network MM panel prefers triplet therapy over doublet as the standard of care for all patients because of improved response rates, depth of response, and rates of progression-free survival (PFS) or overall survival.3 The combination of a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and a corticosteroid remains the cornerstone of frontline treatment for patients, regardless of eligibility for autologous stem cell transplant (ASCT). As an example, the bortezomib/lenalidomide/dexamethasone regimen is a preferred category 1 recommendation for transplant-eligible and -ineligible patients.3

Many agents administered as frontline therapy for patients with MM are used in the relapsed/refractory setting. Choice of therapy is influenced by what was used in the frontline setting, patient comorbidities and organ function, response assessment from prior treatment, tolerability of prior therapy, and time to relapse. Despite numerous treatment combinations, the primary goals of therapy for all patients with MM are disease control, improved quality of life, and prolonged survival. MM remains incurable to date. This article reviews select novel treatments that have recently expanded the therapeutic landscape for patients with MM and highlights others in the pipeline.

Daratumumab as Frontline Treatment for MMDaratumumab (Darzalex), an anti-CD38 monoclonal antibody, was initially approved on November 16, 2015, for the treatment of patients with relapsed/refractory MM.4 The FDA recently approved 2 daratumumab combination regimens as frontline treatment for patients with MM.

The MAIA trial (NCT02252172), an open-label, randomized (1:1), active-controlled phase 3 study, compared daratumumab 16 mg/kg, in combination with lenalidomide (Revlimid), and low-dose dexamethasone (DRd) with lenalidomide and low-dose dexamethasone (Rd) in patients with newly diagnosed MM who were ineligible for ASCT.5 A total of 737 patients were randomized, 368 to the DRd arm and 369 to the Rd arm. MAIA demonstrated an improvement in PFS in the DRd arm compared with the Rd arm. The median PFS had not been reached in the DRd arm and was 31.9 months in the Rd arm (HR, 0.56; 95% CI, 0.43-0.73; P <.0001), representing a 44% reduction in the risk of disease progression or death in patients treated with DRd. In responders, the median time to response was 1.05 months (range, 0.2-12.1) in the DRd group and 1.05 months (range, 0.3-15.3) in the Rd group. The median duration of response had not been reached in the DRd group and was 34.7 months (95% CI, 30.8not estimable [NE]) in the Rd group. In patients with newly diagnosed MM who received DRd, the most frequent (20%) adverse ef fects (AEs) were infusion reactions, diarrhea, constipation, nausea, peripheral edema, fatigue, back pain, asthenia, pyrexia, upper respiratory tract infection, bronchitis, pneumonia, decreased appetite, muscle spasms, peripheral sensory neuropathy, dyspnea, and cough.

The CASSIOPEIA trial (NCT02541383), an open-label, randomized, active-controlled phase 3 study, compared induction and consolidation treatment withbortezomib, thalidomide, and dexamethasone (DVTd) with treatment with bortezomib, thalidomide, and dexamethasone (VTd) in patients with newly diagnosed MM who were eligible for ASCT.6 A total of 1085 patients were randomized, 543 to the DVTd arm and 542 to the VTd arm. CASSIOPEIA demonstrated an improvement in PFS in the DVTd arm compared with the VTd arm. At a median follow-up of 18.8 months, the median PFS had not been reached in either arm. Treatment with DVTd resulted in a reduction in the risk of progression or death by 53% compared with VTd alone (HR, 0.47; 95% CI, 0.33-0.67; P <.0001). In patients with newly diagnosed MM who received DVTd, the most frequent (20%) AEs were infusion reactions, periph eral sensory neuropathy, constipation, asthenia, nausea, peripheral edema, neutropenia, thrombocytopenia, pyrexia, and paresthesia. AEs that occurred with 5% frequency in the DVTd arm were infusion reactions, nausea, neutropenia, thrombocytopenia, lymphopenia, and cough. No significant differences were observed in the number or type of serious AEs between the 2 treatment arms.

Selinexor for Relapsed/Refractory MMSelinexor (Xpovio) offers a novel mechanism of action as a first-in-class selective inhibitor of nuclear export 1 (XPO1).7 XPO1 inhibition leads to accumulation of tumor suppressor proteins in the nucleus; reductions in several oncoproteins, such as cMyc and cyclin D1; cell cycle arrest; and apoptosis of cancer cells. Selinexor in combination with dexamethasone is indicated for adult patients with relapsed/refractory MM who have received at least 4 prior therapies and whose disease is refractory to at least 2 PIs, at least 2 IMiDs, and an anti-CD38 monoclonal antibody.4

Investigators evaluated the efficacy of selinexor plus dexamethasone in the STORM trial (NCT02336815), a multicenter, singlearm, openlabel study.7,8 In STORM part 2, 122 patients were treated with selinexor 80 mg in combination with dexamethasone 20 mg on days 1 and 3 of every week. The overall response rate (ORR) was 25.3% (95% CI, 16.4-36.0), with 1 stringent complete response, no complete responses, 4 very good partial responses, and 16 partial responses. The median time to first response was 4 weeks (range, 1-10).

The median duration of response was 3.8 months (95% CI, 2.3-NE). Common AEs reported in at least 20% of patients included thrombocytopenia, fatigue, nausea, anemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea, and upper respiratory tract infection.

It is important to note the first dose reduction is administered as 100 mg once weekly, followed by 80 mg and 60 mg once weekly for subsequent reductions.7 Patients should receive antiemetic therapy prior to doses of selinexor.

Ongoing Clinical TrialsInvestigators continue to evaluate novel drug mechanisms and therapeutic combinations, aiming to optimize treatment outcomes and safety for patients throughout all stages of disease. B-cell maturation antigen (BCMA) targeting has demonstrated efficacy in treating MM.9 Anti-BCMA chimeric antigen receptor T-cell therapies, such as idecabtagene vicleucel, received FDA breakthrough therapy designation for treating relapsed/refractory MM based on data from the phase 1 CRB-401 trial. Antibody-drug conjugates such as belantamab mafodotin have demonstrated an ORR of 60% with a median duration of response >1 year, based on findings from the phase I DREAMM-1 trial.10

The treatment landscape of MM is extremely bright, with novel agents and combinations in various clinical trial phases. Importantly, clinicians should remain up-to-date on novel therapies to provide optimal and safe therapeutic options for patients in all phases of treatment.

REFERENCES

Read the original:

Updates in the Management of Multiple Myeloma - Pharmacy Times

Protein Associated with Leukemia May Lead to Targeted Therapy for Currently Incurable Acute Lymphoblastic Leukemia – Pharmacy Times

Protein Associated with Leukemia May Lead to Targeted Therapy for Currently Incurable Acute Lymphoblastic Leukemia

ALL is a form of blood cancer that primarily affects children and young people and causes large quantities of malignant progenitor cells to build in a patients blood instead of healthy white blood cells. This is often caused by 2 chromosomes fusing together to create new abnormal genes that disrupt the system controlling normal blood development. Because of this process, certain types of leukemia are extremely resistant and unable to be cured with intensive chemotherapy or stem cell transplantation.

Researchers analyzed a protein called TCF3-HLF, which is typically associated with this type of leukemia and does not occur naturally. It is produced through the fusion of 2 chromosomes and contains elements of transcription factors, which activate the transcription of certain genes.

The analysis revealed that TCF3-HLF activates a whole range of genes, but it does so in the wrong contextat the wrong point in the blood development process. The formation of malignant white blood cells is then triggered, causing leukemia.

The study authors also discovered that the abnormal protein does not act alone, but instead gathers more than 100 other proteins around it, which helps to activate the genes. The researchers investigated the function of the individual proteins in the genetic machinery and used it to identify key elements that could be targeted through therapy.

Using the CRISPR/Cas9 method, researchers detached the specific parts they had identified from the machinery and found 11 critical factors that are crucial to the build-up of malignant abnormal blood cells in leukemia.

One of the essential components now identified is the protein EP300, a cofactor that boosts gene activation. The researchers used a new kind of substance called A-485, known to bind to EP300 and inhibit its activity. When A-485 was administered to human leukemia cells, the malignant cells died off.

The study authors noted that it is possible to stop the fundamental driving force behind the leukemia directly and thus develop a targeted type of therapy. Given that other forms of leukemia are caused by similar mechanisms, it may also be possible to identify a common denominator for developing new drugs to combat cancer.

REFERENCE

New approach to treating incurable leukemia in children discovered [press release]. University of Zurich. BioPortfolio website. Published November 24, 2019. https://www.bioportfolio.com/news/article/4148041/New-approach-to-treating-incurable-leukemia-in-children-discovered.html. Accessed December 4, 2019.

See original here:

Protein Associated with Leukemia May Lead to Targeted Therapy for Currently Incurable Acute Lymphoblastic Leukemia - Pharmacy Times

BELINDA Trial Tests Earlier Use of Tisa-Cel in Aggressive B-Cell Non-Hodgkin Lymphoma – Cancer Therapy Advisor

A multicenter phase 3 trial began enrolling patients earlier this year to test the safety and efficacy of tisagenlecleucel (tisa-cel/Kymriah) as a second-line therapy for aggressive B-cell non-Hodgkin lymphoma (NHL).

Tisa-cel, an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy, has already been approved for use in patients who have relapsed after receiving 2 lines of therapy. But its possible that, if administered sooner across treatment regimens, CAR-T could help more patients avoid relapse. The new study on this topic, known as BELINDA, aims to answer that question.

The hypothesis is that CAR-T cells should improve upon progression-free survival as compared to standard of care, said Michael Bishop, MD, director of the hematopoietic stem cell transplantation program at the University of Chicago Medicine, Illinois, and one of the BELINDA coauthors. Dr Bishop presented the study protocol at the 34th Annual Meeting & Preconference Programs of the Society for Immunotherapy of Cancer, or SITC 2019, in National Harbor, Maryland.1

Around a third of patients with non-Hodgkin lymphoma (NHL) will relapse after receiving first-line immunochemotherapy, and another 10% to 15% do not respond to initial treatment. For these patients, the outlook is grim: median overall survival is less than 12 months. Second-line treatment consists of high-dose chemotherapy combined with autologous stem cell transplant, but fewer than half of patients will qualify for a transplant. Youve got half the patients who wont get the transplant, and the other half that do, only a quarter of those will have sustained remission, said Dr Bishop. Its a large unmet patient need.

Dr Bishop went on to explain that previous trials have indicated that some 30% to 40% of patients receiving CAR-T therapy for multiply relapsed or refractory NHL have achieved long-term remission. The other exciting thing about this trial is its moving CAR-T up the treatment algorithm, he said.

The BELINDA trial is a multicenter, phase 3, open-label trial, in which patients are randomly selected to receive treatment in 1 of 2 arms: tisa-cel, or standard of care. Similar to the ZUMA-7 trial,2 which tested another CAR-T therapy called axicabtagene ciloleucel (Yescarta), BELINDA is enrolling patients whose disease either does not respond to first-line therapy (rituximab and anthracycline) or has returned within 12 months, and who are eligible for autologous stem cell transplant.

More:

BELINDA Trial Tests Earlier Use of Tisa-Cel in Aggressive B-Cell Non-Hodgkin Lymphoma - Cancer Therapy Advisor

Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic…

DetailsCategory: Small MoleculesPublished on Monday, 23 December 2019 16:05Hits: 847

NEW YORK, NY, USA and LONDON, UK I December 23, 2019 I Akari Therapeutics, Plc (Nasdaq:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces that a U.S. Food and Drug Administration (FDA) investigational new drug application (IND) is open for its multicenter Phase III study for the treatment of pediatric HSCT-TMA with nomacopan, allowing clinical sites to open in the first quarter of 2020.

With the pediatric HSCT-TMA IND now open we look forward to starting the pivotal Phase III study of nomacopan in HSCT-TMA, a potential treatment for a high risk pediatric population that suffer very high death rates and for which there are currently no approved therapies. If successful, we expect HSCT-TMA to be a gateway into a range of other poorly treated orphan TMAs, commented Clive Richardson, CEO of Akari Therapeutics. In addition, following the recent successful completion of our Phase II bullous pemphigoid study, we expect data from our Phase I/II atopic keratoconjunctivitis trial in early 2020 and interim data from our Phase III paroxysmal nocturnal hemoglobinuria trial in the first half of 2020.

HSCT-TMA is an orphan hematological condition that occurs in up to 30% of patients who have received a hematopoietic stem cell transplant (HSCT). There are no approved treatments for pediatric HSCT-TMA, and it has an estimated mortality rate of more than 80% in children with the severe form of the disease1. It is this severe form that is being targeted with nomacopan which is a bifunctional inhibitor of complement C5 and leukotriene B4 (LTB4). Following the recent end-of-Phase II meeting with the FDA, Akari has now opened an IND to initiate its pivotal pediatric HSCT-TMA study based on a single arm responder-based design. Recruitment will be focused on specialist pediatric sites in the U.S. and Europe where treatment tends to be concentrated in specialist centres.

Whilst the role of complement inhibition is understood to play an important role in pediatric HSCT-TMA, the Company believes LTB4 may also be an important target in reducing epithelial activation in both TMA and graft versus-host disease2 (GVHD) which often occur simultaneously. The Company believes daily dosing with nomacopan may also be of particular advantage in facilitating more complete complement suppression, especially in HSCT-TMA patients with high transfusion requirements.

As previously announced, this two-part pivotal Phase III study of nomacopan in pediatric patients with HSCT-TMA is based on guidance from the Companys end-of-Phase II meeting with the FDA. Part A of the trial is a dose confirmation study. Part B of the trial is a single arm responder-based efficacy study that will follow an interim analysis of Part A and a meeting with the FDA. Akari has both FDA fast track and orphan status for this program.

1 Sonata Jodele, et al. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation associated thrombotic microangiopathy. Transfus Apher Sci . 2016 April; 54(2): 181190

2 Takatsuka, et al. Predicting the severity of intestinal graft-versus-host disease from leukotriene B4 levels after bone marrow transplantation. Transplantation 2000, 26: 1313-1316

About Akari Therapeutics

Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug candidate, nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4). Nomacopan is currently being clinically evaluated in four indications: bullous pemphigoid (BP), atopic keratoconjunctivitis (AKC), thrombotic microangiopathy (TMA), and paroxysmal nocturnal hemoglobinuria (PNH). Akari believes that the dual action of nomacopan on both C5 and LTB4 may be beneficial in AKC and BP. Akari is also developing other tick derived proteins, including longer acting versions.

SOURCE: Akari Therapeutics

See the original post:

Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic...

Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy fo | DDDT – Dove Medical Press

Liming Wang,1,* Shigao Huang,2,* Shimei Li,1 Ming Li,1 Jun Shi,1 Wen Bai,1 Qianyun Wang,1 Libo Zheng,3 Yongjun Liu3

1Cell Therapy Center, 986 Hospital of Peoples Liberation Army Air Force, Xian, Shaanxi, Peoples Republic of China; 2Cancer Center, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macao SAR, Peoples Republic of China; 3Stem Cell Biology and Regenerative Medicine Institution, Yi-Chuang Institute of Bio-Industry, Beijing, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Shigao HuangCancer Center, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Room 3013, Building N-22, Taipa, Macau, Peoples Republic of ChinaEmail huangshigao2010@aliyun.comYongjun LiuStem Cell Biology and Regenerative Medicine Institution, Yi-Chuang Institute of Bio-Industry, No. 35, Jinghai 3 Road Economic-Technological Development Area, Beijing, Peoples Republic of ChinaEmail andyliuliu2001@aliyun.com

Background: The traditional anti-inflammation disease-modifying anti-rheumatic drugs (DMARDs) have limited therapeutic effects in rheumatoid arthritis (RA) patients. We previously reported the safety and efficacy of umbilical cord mesenchymal stem cell (UC-MSC) treatment in RA patients that were observed for up to 8 months after UC-MSC infusion. The aim of this study is to assess the long-term efficacy and safety of UC-MSC along with DMARDs for the treatment of RA.Methods: 64 RA patients aged 1864 years were recruited in the study. During the treatment, patients were treated with 40 mL UC-MSC suspension product (2 107 cells/20 mL) via intravenous injection immediately after the infusion of 100 mL saline. The serological markers tests were used to assess safety and the 28-joint disease activity score (DAS28) and the Health Assessment Questionnaire (HAQ) to assess efficacy.Results: 1 year and 3 years after UC-MSC cells treatment, the blood routine, liver and kidney function and immunoglobulin examination showed no abnormalities, which were all in the normal range. The ESR, CRP, RF of 1 year and 3 years after treatment and anti-CCP of 3 years after treatment were detected to be lower than that of pretreatment, which showed significant change (P < 0.05). Health index (HAQ) and joint function index (DAS28) decreased 1 year and 3 years after treatment than before treatment (P < 0.05).Conclusion: UC-MSC cells plus DMARDs therapy can be a safe, effective and feasible therapeutic option for RA patients.

Keywords: rheumatoid arthritis, umbilical cord mesenchymal stem cell, cell therapy

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read more here:

Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy fo | DDDT - Dove Medical Press

Aspen Neuroscience Receives $6.5M for Parkinson’s Stem Cell Therapy – Parkinson’s News Today

Aspen Neuroscience, a new biotech company, has raised $6.5 million to develop cell therapies for Parkinsons disease using patients own cells.

The company was co-founded by renowned stem cell scientists Jeanne F. Loring, PhD, and Andres Bratt-Leal, PhD, and initially supported by Summit for Stem Cell, a non-profit organization that provides a variety of services for Parkinsons patients.

Parkinsons hallmark motor symptomsinclude tremor, slowness of movement (bradykinesia), stiffness (rigidity), uncontrollable movements (dyskinesia), and poor balance.

As the disease progresses, patients typically need to gradually increase their dopaminergic therapeutic dose for maximum benefit. Even after that they might sometimes experience reappearance or worsening of symptoms due to diminishing effects of dopaminergic therapy, known was off periods.

Importantly, dopaminergic therapy is delivered to areas of the brain other than the striatum, a key motor control region severely affected in Parkinsons disease. Because of the therapys off-target behavior, patients also may experience side effects such as hallucinations or cognitive impairment.

Aspen wants to combine its expertise in stem cell biology, genomics and neurology and develop the first autologous (self) stem cell-based therapy for Parkinsons disease.

In this type of cell therapy, a patients own cells (usually skin cells) are reprogrammed back into a stem cell-like state, which allows the development of an unlimited source of almost any type of human cell needed, including dopamine-producing neurons, which are those mainly affected by this disorder.

Because these cells are derived from patients, they do not carry the risk of being rejected once re-implanted, eliminating the need for immunosuppressive complementary therapies, which carry serious side effects such as infections and possibly limiting therapeutic potential.

In theory, replacing lost dopaminergic neurons with new stem cell-derived dopamine-producing ones could potentially ease or reverse motor symptoms associated with the disease.

Aspen is developing a restorative, disease modifying autologous neuron therapy for people suffering from Parkinsons disease, Howard J. Federoff, MD, PhD, Aspens CEO, said in a press release.

We are fortunate to have such a high-caliber scientific and medical leadership team to make our treatments a reality. Our cell replacement therapy, which originated in the laboratory of Dr. Jeanne Loring and was later supported by Summit for Stem Cell and its President, Ms. Jenifer Raub, has the potential to release dopamine and reconstruct neural networks where no disease-modifying therapies exist, Federoff said.

The companys lead product (ANPD001) is undergoing investigational new drug (IND)-enabling studies for the treatment of sporadic Parkinsons disease. Aspen experts also are developing a gene-editing treatment (ANPD002) for familial forms of Parkinsons, starting with the most common genetic variant in the GBAgene, which provides instructions to make the enzyme beta-glucocerebrosidase.

The new seed funding round was led by Domain Associates and Axon Ventures, with additional participation from Alexandria Venture Investments, Arch Venture Partners, OrbiMed and Section 32, according to the press release.

With over three years of experience in the medical communications business, Catarina holds a BSc. in Biomedical Sciences and a MSc. in Neurosciences. Apart from writing, she has been involved in patient-oriented translational and clinical research.

Total Posts: 208

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

See original here:

Aspen Neuroscience Receives $6.5M for Parkinson's Stem Cell Therapy - Parkinson's News Today

Aspen Neuro Bags $6.5M to Test Parkinson’s Disease Stem Cell Therapy – Xconomy

XconomySan Diego

Nearly nine years ago Jeanne Loring and her colleagues at Scripps Research debuted a test that leveraged advances in genomics and data science to determine, without testing in animals, whether human stem cells were pluripotent, or able to become any type of cell in the body.

Being able to prove that has become increasingly important as scientists look to induced pluripotent stem cells (iPSCs)mature, specialized cells that have been reprogrammed as immature cells, regaining the capability of becoming any type of cellas material for new regenerative medicines.

Now Loring and Andres Bratt-Leal, who joined her lab in 2012 as a post-doctoral researcher, have founded a biotech that combines stem cell biology and genomics know-how to advance a potential cell therapy for Parkinsons disease.

The startup announced Thursday it raised a seed round of $6.5 million to support its work. Aspens lead drug candidate, which is in preclinical testing, is intended to replace neurons in the brains of people with the disease, which causes those cells to become damaged or die.

When people with Parkinsons disease lose neurons, they also lose a chemical messenger the cells produce, called dopamine. Without dopamine, communication between nerve cells falters, which leads to the debilitating motor problems that characterize the disease. Existing Parkinsons drugs aim to alter dopamine levels. Aspen, however, wants to fix the upstream problem that leads to those lowered levels by reconstructing patients damaged neural networks.

The cell therapy would involve harvesting patients own living cells through a skin biopsy, reprogramming them to immature cells, or iPSCs, then further engineering them to become predisposed to mature into neurons. Once enough of those cells have been grown in the lab, those neuron precursor cells would be delivered directly to the brain.

Using a patients own cells avoids the dangerous immune system reactions that can occur when donor cells are used in such therapies, and obviates the need for immunosuppression drugs. Two cell therapies that use genetic engineering have been approved by the FDA, both of which take and tweak patients T cells into treatments for cancer. Stem cell transplants have been used to treat some cancers.

Aspen worked to ensure the company could ably manufacture a so-called autologous replacement cell therapy, or one from a patients one cells, by improving the process of differentiating iPSCs into dopamine neurons, Loring says. And the group developed another predictive genomic-based test, similar to the effort Loring spearheaded nearly a decade ago to determine whether cells were pluripotent, that can detect which iPSCs are destined to become neurons.

(Bratt-Leal) put his biological engineering expertise into coming up with a way that was reproducible, that we would get the same cells no matter who we got the original cells from, she says.

The company plans to test the therapy in patients that they determine, through genomic testing, have the most common form of Parkinsons, which is referred to as sporadic and arises without a clear genetic predisposition. It also has a second treatment in the works that it intends to develop for patients with familial forms of the disease, and uses a gene editing toolyet to be selectedto alter their stem cells during the reprogramming process.

Howard Federoff, who was most recently vice chancellor for health affairs and CEO of the UC Irvine Health system, is Aspens CEO. Federoff says he has come to believe that Parkinsons patients need more than just to stabilize their disease They need to turn the clock back.

Many companies are working on drugs to treat Parkinsons, but most are meant to manage symptoms rather than reverse the disease. Levodopa, which supplants missing dopamine, is used widely, but it can cause side effects, including involuntary movement called dyskinesia; and, as the disease progresses, the drug eventually stops working between doses.

Aspen claims it is the only company working toward an autologous neuron replacement. The company, however, will need to raise a Series A round to move its drug candidates through Phase 2 proof-of-concept trials, Loring says.

The company raised its seed round from a group of investors including Domain Associates, Alexandria Venture Investments, Arch Venture Partners, Axon Ventures, OrbiMed, and Section 32. Initially, it was financed through grants from Summit for Stem Cell, a San Diego-based nonprofit.

Sarah de Crescenzo is an Xconomy editor based in San Diego. You can reach her at sdecrescenzo@xconomy.com.

Read more:

Aspen Neuro Bags $6.5M to Test Parkinson's Disease Stem Cell Therapy - Xconomy

Aspen Neuroscience gets funding to pursue personalized cell therapy for Parkinsons disease – The San Diego Union-Tribune

Aspen Neuroscience, a new San Diego biotech company working on stem cell treatment for Parkinsons disease, has come out of stealth mode and raised $6.5 million to pursue clinical testing for its therapy.

Co-founded by well-known stem cell scientist Jeanne Loring, Aspen Neuroscience proposes creating stem cells from modified skin cells of Parkinsons patents via genetic engineering.

The stem cells, which can become any type of cell in the body, then would undergo a process that makes them specialize into dopamine-releasing neurons.

People with Parkinsons lose a large number up to 50 percent at diagnosis of specific brain cells that make the chemical dopamine.

Without dopamine, nerve cells cannot communicate with muscles and people are left with debilitating motor problems.

Once these modified skin cells have been engineered to specialize in producing dopamine, they can be transplanted into the Parkinsons patient to restore the types of neurons lost to the disease.

The reason we called it Aspen is because l was raised in the Rocky Mountain states, said Loring. When there is a forest fire in the Rockies, the evergreens are wiped out but the aspens are the fist that regenerate after the burn. So it is a metaphor for regeneration.

Aspen still has a long way to go before its proposed therapy would be available to Parkinsons patients. It has been meeting with the U.S. Food and Drug Administration to provide animal trial data and other information in hopes of getting permission to start human clinical trials.

But the company expects the earliest it would get the go-ahead from FDA to start human trials would be 2021.

Loring has been working on the therapy for eight years. She is professor emeritus and founding director of the Center for Regenerative Medicine at the Scripps Research Institute.

Loring co-founded the 20-employee company with Andres Bratt-Leal, a former post-doctoral researcher in Lorings lab at Scripps.

Joining them as Aspens Chief Executive is Dr. Howard Federoff, former vice chancellor for health affairs and chief executive of the University of California Irvine Health System.

Federoff said the company is the only one pursuing the use of Parkinsons patients own cells as part of neuron replacement therapy.

Aspens proprietary approach does not require the use of immuno-suppression drugs, which can be given when transplanted cells come from another person and perhaps limit the effectiveness of the treatment.

Aspens approach is a therapy that is likely to benefit from the fact that your own cells know how to make the best connections with their own target cells in the brain, even in the setting of Parkinsons disease, said Federoff. So when transplanted it is able to set back the clock on Parkinsons.

In addition to Aspens main therapy, it is researching a gene-editing treatment for forms of Parkinsons common in certain families.

Aspens research work up to now has been supported by Summit for Stem Cell, a non-profit on which provides a variety of services for people with Parkinsons disease.

The new seed funding round was led by Domain Associates and Axon Ventures, with additional participation from Alexandria Venture Investments, Arch Venture Partners, OrbiMed and Section 32.

Aspens financial backing, combined with its experienced and proven leadership team, positions it well for future success, said Kim Kamdar, a partner at Domain Associates. Domain prides itself on investing in companies that can translate scientific research into innovative medicines and therapies that make a difference in peoples lives. We clearly see Aspen as fitting into that category, as it is the only company using a patients own cells for replacement therapy in Parkinsons disease.

The rest is here:

Aspen Neuroscience gets funding to pursue personalized cell therapy for Parkinsons disease - The San Diego Union-Tribune

Global Allogeneic Stem Cells Market 2020-2024 | Evolving Opportunities with Biosolution Co. Ltd. and Cynata Therapeutics Ltd. | Technavio – Business…

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global allogeneic stem cells market and the market is poised to grow by USD 1.24 billion during 2020-2024 at a CAGR of over 12% during the forecast period. Request Free Sample Pages

Read the 131-page research report with TOC on "Allogeneic Stem Cells Market Analysis Report by geography (Asia, Europe, North America, and ROW), by application (regenerative therapy and drug discovery and development), and segment forecasts, 2020-2024".

https://www.technavio.com/report/allogeneic-stem-cells-market-industry-analysis

The new product approvals and special drug designations are anticipated to boost the growth of the market. Based on the application, the allogeneic stem cells market has been segmented into regenerative therapy and drug discovery and development. Manufacturers are increasingly emphasizing innovations and improvisation in the development of regenerative therapies. Many of the regenerative therapeutic candidates have obtained approval for clinical trials in the US, Europe, and APAC due to the efficacy of allogeneic stem cell therapeutics. This is encouraging market players to launch new product lines to stimulate the overall product demand for stem or regenerative therapy using allogeneic stem cell therapeutics and provide better options for their customers. Thus, new product approvals are expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Allogeneic Stem Cells Market Companies:

Biosolution Co. Ltd.

Biosolution Co. Ltd. is headquartered in South Korea (Republic of Korea) and operates the business under its Unified business segment. The company offers an allogeneic keratinocyte spread medication, Keraheal-Allo, that promotes skin regeneration.

Cynata Therapeutics Ltd.

Cynata Therapeutics Ltd. is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sales of innovative therapeutics for the treatment of various diseases. The company provides a mesenchymal stem cell product, Cymerus, which is used to treat graft-versus-host disease.

JCR Pharmaceuticals Co. Ltd.

JCR Pharmaceuticals Co. Ltd. is headquartered in Japan and operates under two business segments, namely Pharmaceuticals, and Medical Devices and Laboratory Equipment. The company offers a regenerative medical product, TEMCELL HS Injection, which uses human mesenchymal stem cells for the treatment of acute graft-versus-host disease.

Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc. is headquartered in the US and offers products through its Unified business segment. The company provides OpRegen, which is currently being tested in a Phase I/IIa clinical trial. This product is intended for the treatment of dry AMD.

MEDIPOST Co. Ltd.

MEDIPOST Co. Ltd. is headquartered in South Korea (Republic of Korea) and offers products through its Unified business segment. The company provides an allogeneic umbilical cord blood-derived mesenchymal stem cell drug, CARTISTEM, which is used for the treatment of knee cartilage defects.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Allogeneic Stem Cells Application Outlook (Revenue, USD Million, 2020-2024)

Allogeneic Stem Cells Regional Outlook (Revenue, USD Million, 2020-2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Health Care include:

Cancer Stem Cell Therapeutics Market Global Cancer Stem Cell Therapeutics Market by type (allogeneic stem cell transplant and autologous stem cell transplant) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Continue reading here:

Global Allogeneic Stem Cells Market 2020-2024 | Evolving Opportunities with Biosolution Co. Ltd. and Cynata Therapeutics Ltd. | Technavio - Business...

BioRestorative Therapies Featured in IEEE Pulse Magazine’s Cover Story About Stem Cell Therapies for Low Back Pain – GlobeNewswire

MELVILLE, N.Y., Dec. 16, 2019 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (BioRestorative or the Company) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, announced today feature coverage in the news outlet, IEEE Pulse, a magazine of the IEEE Engineering in Medicine and Biology Society. According to IEEE, it is the worlds largest technical professional organization for the advancement of technology.

To view the IEEE Pulse Magazines article featuring BioRestorative, click here.

The published cover-story article features commentary from Francisco Silva, Chief Scientist and Vice President of Research and Development for BioRestorative, regarding BRTX-100, the Companys lead therapeutic candidate for chronic lumbar disc disease. Once the U.S. Food and Drug Administration (FDA) authorizes the sale of BRTX-100, we would ship it to your doctor, and with a 30-minute procedure the material would be injected into your disc in a 1.5 ml solution, explains Silva. He elaborates on the product, discussing growing and expanding stem cells from the patients bone marrow under hypoxic conditions that mimic those in the normal intervertebral space. We are enriching the cells to be able to survive in this harsh environment, says Silva.

In addition to BRTX-100, the magazine article also highlights BioRestoratives other research pursuit, its ThermoStem program, utilizing brown adipose (fat) derived stem cells to target treatment of metabolic diseases and disorders, like diabetes, obesity and hypertension.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

Disc/Spine Program (brtxDISC): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a persons own) cultured mesenchymal stem cells collected from the patients bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 production process utilizes proprietary technology and involves collecting a patients bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patients damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain due to painful degenerative discs.

Metabolic Program (ThermoStem): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, whether the Company will be able to consummate the private placement and the satisfaction of closing conditions related to the private placement and those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:Email: ir@biorestorative.com

Read the original post:

BioRestorative Therapies Featured in IEEE Pulse Magazine's Cover Story About Stem Cell Therapies for Low Back Pain - GlobeNewswire

Regenerative Stem Cell Therapy With Novita Spa On The Square Medical Rejuvenation Clinic – KXAN.com

The Groundbreaking Series That Puts Innocent Civilians in Jail Returns For Its Most Dangerous Season Yet

For the first time in "60 Days In" history, more participants struggle to survive the intense program and are forced to quit early. After two decades, the Etowah County Detention Center is under new management and the new Sheriff is determined to make a change. In his first week, he decided to shakedown the facility and in one day alone, found more than 200 broken door locks, drugs and removed more than two tons of contraband. With no time to lose, Sheriff Horton along with Chief Peek and select members of their team have agreed to embed innocent participants to uncover the issues that plague the facility. This season, the participants will face the biggest challenge of their lives in an effort to rid a jail, that is in dire need of help, of contraband and corruption before it is too late.

View original post here:

Regenerative Stem Cell Therapy With Novita Spa On The Square Medical Rejuvenation Clinic - KXAN.com

Orbiting Organoids: Research in Space to Unveil New Neurodegeneration Insight – Xconomy

XconomyNational

More than 250 miles above the Earths surface aboard the International Space Station, a first-in-kind study of neurodegenerative disease is expected to reveal never-before-seen cell interactions.

The National Stem Cell Foundation (NSCF) is funding the study, which is the result of a bi-coastal collaboration between the New York Stem Cell Foundation (NYSCF) Research Institute and Aspen Neuroscience, a San Diego startup developing personalized cell therapies for Parkinsons disease.

Collaborating with the New York Stem Cell Foundation (NYSCF) Research Institute on the other side of the country, the two teams have been working together for more than two years, exchanging and sharing technology to develop patient-derived, induced pluripotent stem cell (iPSC) organoid models.

The 3D human organoid models were launched to the International Space Station earlier this month for research in microgravity, with the goal of furthering our understanding of neurogenerative diseases back on earth.

The models incorporate microglia, the inflammatory cells of the immune system that are implicated in the development of Parkinsons, multiple sclerosis, and other neurodegenerative diseases, explains Paula Grisanti, CEO of NSCF.

Studying the 3D models in microgravity, researchers are able to observe cell interaction, gene expression, and other developments not seen in a regular lab.

Its not possible for you to have this same 3D model of cell interaction on Earth. This will be the first time in space where we can see these in 3D, Grisanti tells Xconomy.

Cells behave differently in space, though its not completely understood why. Cartilage grows faster and bigger, proteins fold differently, and cells mature more rapidly. Being able to see this happen in real-timethe models will be filmed for the full 30 dayswill offer researchers unprecedented insight into neurodegenerative disease.

To see how those cells talk to each other for 30 days when they are up on the international space station will allow scientists to see the point at which things start to go awry in those diseases and hopefully identify a new place or a new point at which you could intervene with a cell or gene therapy that may or may not currently exist, says Grisanti.

The research will touch back down to earth in early January at which time both labs will analyze the models to determine what exactly happened during their time in space. All data will be published for full dissemination.

(Paul Kuehl, Jason Rexroat, Gentry Barnett, Valentina Fossati, Jason Stein, Scott Noggle, Jana Stoudemire. Image courtesy of Space Tango)

NSCF has budgeted for a year of post-flight research after which the researchers will send the models back to the space station for a second flight to confirm what they saw and test new hypotheses, explains Grisanti. A second year of post-flight research also is funded, as is a second flight at the end of 2020.

We know were going to see something new because it has never been done before, says Grisanti, who explains that the budget and project will continue to be extended as long as new theories and opportunities are being developed.

The December flight was the second for the research teams at Apsen and NYSCF. A preliminary flight was conducted in July 2019 to test the hardware systems and prepare for the SpaceX CRS-19 launch.

Aspen has also been pressing ahead with its own research on solid ground. Last week, the company closed a $6.5 million seed round led by Domain Associates and Axon Ventures.

Aspens cell therapy approach was developed by its co-founders, Jeanne Loring, professor emeritus and founding director of the Center for Regenerative Medicine at The Scripps Research Institute and Andres Bratt-Leal, a former post-doctoral researcher in Lorings lab. Also serving as Aspens chief scientific officer, Jeanne Loring was in May named Xconomys Stem Cell Pioneer of the Year.

(Main image: Experiment loaded for launch at Kennedy Space Center. Courtesy of Space Tango)

Melissa Fassbender is an Xconomy editor based in Chicago. You can reach her at mfassbender@xconomy.com.

Read more:

Orbiting Organoids: Research in Space to Unveil New Neurodegeneration Insight - Xconomy

Scientists Take Stem Cells and Convert Them to Heart Pacemaker Cells – Technology Networks

University of Houston associate professor of pharmacology Bradley McConnell is helping usher in a new age of cardiac pacemakers by using stem cells found in fat, converting them to heart cells, and reprogramming those to act as biologic pacemaker cells. He is reporting his work in theJournal of Molecular and Cellular Cardiology.

The new biologic pacemaker-like cell will be useful as an alternative treatment for conduction system disorders, cardiac repair after a heart attack and to bridge the limitations of the electronic pacemaker.

"We are reprogramming the cardiac progenitor cell and guiding it to become a conducting cell of the heart to conduct electrical current," said McConnell.

McConnell's collaborator, Robert J. Schwartz, Hugh Roy and Lillian Cranz Cullen Distinguished Professor of biology and biochemistry, previously reported work on turning the adipogenic mesenchymal stem cells, that reside in fat cells, into cardiac progenitor cells. Now those same cardiac progenitor cells are being programmed to keep hearts beating as a sinoatrial node (SAN), part of the electrical cardiac conduction system (CCS).

The SAN is the primary pacemaker of the heart, responsible for generating the electric impulse or beat. Native cardiac pacemaker cells are confined within the SAN, a small structure comprised of just a few thousand specialized pacemaker cells. Failure of the SAN or a block at any point in the CCS results in arrhythmias.

More than 600,000 electronic pacemakers are implanted in patients annually to help control abnormal heart rhythms. The small mechanical device is placed in the chest or abdomen and uses electrical pulses to prompt the heart to beat normally. In addition to having the device regularly examined by a physician, over time an electronic pacemaker can stop working properly.

"Batteries will die. Just look at your smartphone," said McConnell. "This biologic pacemaker is better able to adapt to the body and would not have to be maintained by a physician. It is not a foreign object. It would be able to grow with the body and become much more responsive to what the body is doing."

To convert the cardiac progenitor cells, McConnell infused the cells with a unique cocktail of three transcription factors and a plasma membrane channel protein to reprogram the heart cells in vitro.

"In our study, we observed that the SHOX2, HCN2, and TBX5 (SHT5) cocktail of transcription factors and channel protein reprogrammed the cells into pacemaker-like cells. The combination will facilitate the development of cell-based therapies for various cardiac conduction diseases," he reported.

Reference: Raghunathan et al. (2019).Conversion of human cardiac progenitor cells into cardiac pacemaker-like cells. Journal of Molecular and Cellular Cardiology. DOI: https://doi.org/10.1016/j.yjmcc.2019.09.015.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Here is the original post:

Scientists Take Stem Cells and Convert Them to Heart Pacemaker Cells - Technology Networks

Global Stem Cell Therapy Market to Become a Worth US$ 4759.27 Million By 2024 – E-Industry News

The Global Stem Cell Therapy Market Set For Rapid Growth, To Reach Around USD 4759.27 Million By 2024Research Report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profitability.The global Stem Cell Therapy Market report is a systematic study of the globalStem Cell Therapy Marketintroducing the advanced state of affairs in the market as well as schemes that aid in its enlargement in the coming years. The report evaluates several factors determining the market expansion as well as the volume of the whole Stem Cell Therapy Market. The report states the aggressive vendor scenery of the market together with the profiles of some of the leading market players. The most important players in the Stem Cell Therapy Market are also discussed in the report.

This Research will help you grow your Business: [Download free Sample PDF of This Research Report]

Some of the Major Stem Cell Therapy Market Players Are:

The report covers the product contributions, revenue generated, segmentation, and business summarization of the foremost players. The report provides data taking into consideration the latest improvements in the global Stem Cell Therapy Market while estimating the contribution in the market of the most important players in the near future. The report estimates the limitation and power of the leading players via SWOT analysis and assesses their growth in the market. Additionally, the key product categories and segments as well as the sub-segments of the global market are clarified in the report.

The market assessment is also estimated throughout the research as well as concludes the data using Porters five analysis on the market enlargement.Further, the report also scrutinizes the Stem Cell Therapy Market based on the manufactured goods categories and customer segments as well as the development of each segment is calculated over the predicted time.

Request Free research report Brochure @https://www.zionmarketresearch.com/requestbrochure/stem-cell-therapy-market

The report collects information accumulated from various authoritarian organizations to estimate the growth of the segments. Additionally, the study also evaluates the global Stem Cell Therapy Market on the basis of the topography and analyzes the macro- and microeconomic features determining the market expansion in every area. Furthermore, the Stem Cell Therapy Market is classified on the basis of various regions.

The Stem Cell Therapy Market segmented by regions/countries:

Browse Press Release:https://www.zionmarketresearch.com/news/stem-cell-therapy-market

Highlights of Stem Cell Therapy Market Report:

1) Global Stem Cell Therapy Market share & sales assessments on the basis of regional and country level segments.

2) Industry share analysis of the top market players.

3) Strategic recommendations for the new companies.

4) Market forecasts for 5 years of all the mentioned segments, sub segments and the regional markets.

5) Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations).

6) Competitive landscaping mapping the key trends.

7) Company profiles with their strategies, financials, and recent developments.

8) Production Supply chain trends analysis latest technological advancements.

Inquire more about this report @https://www.zionmarketresearch.com/inquiry/stem-cell-therapy-market

Objective of Studies:

1. To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global Stem Cell Therapy Market.

2. To provide insights about factors affecting the market growth. To analyse the Stem Cell Therapy Market based on various factors- price analysis, supply chain analysis, Porte five force analysis etc.

3. To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, Latin America and Rest of the World.

4. To provide country level analysis of the market with respect to the current market size and future prospective.

5. To provide country level analysis of the market for segment by application, product type and sub-segments.

6. To provide strategic profiling of key players in the market, comprehensively analysing their core competencies, and drawing a competitive landscape for the market.

7. To track and analyse competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Stem Cell Therapy Market.

Why Trust ZMRs Analytical Insights?

Target Audience of Stem Cell Therapy Market:

Manufacturer / Potential Investors

Traders, Distributors, Wholesalers, Retailers, Importers and Exporters

Association and government bodies

Also, Research Report Examines:

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Link:

Global Stem Cell Therapy Market to Become a Worth US$ 4759.27 Million By 2024 - E-Industry News

Stem Cell Therapy Market Detailed Analysis and Forecast 2017-2025 – 101Newsindustry

Stem Cell Therapy Market: Snapshot

Of late, there has been an increasing awareness regarding the therapeutic potential of stem cells for management of diseases which is boosting the growth of the stem cell therapy market. The development of advanced genome based cell analysis techniques, identification of new stem cell lines, increasing investments in research and development as well as infrastructure development for the processing and banking of stem cell are encouraging the growth of the global stem cell therapy market.

To know Untapped Opportunities in the MarketCLICK HERE NOW

One of the key factors boosting the growth of this market is the limitations of traditional organ transplantation such as the risk of infection, rejection, and immunosuppression risk. Another drawback of conventional organ transplantation is that doctors have to depend on organ donors completely. All these issues can be eliminated, by the application of stem cell therapy. Another factor which is helping the growth in this market is the growing pipeline and development of drugs for emerging applications. Increased research studies aiming to widen the scope of stem cell will also fuel the growth of the market. Scientists are constantly engaged in trying to find out novel methods for creating human stem cells in response to the growing demand for stem cell production to be used for disease management.

It is estimated that the dermatology application will contribute significantly the growth of the global stem cell therapy market. This is because stem cell therapy can help decrease the after effects of general treatments for burns such as infections, scars, and adhesion. The increasing number of patients suffering from diabetes and growing cases of trauma surgery will fuel the adoption of stem cell therapy in the dermatology segment.

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Get Discount on Latest Report @CLICK HERE NOW

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Request TOC of the Reportfor more Industry Insights @CLICK HERE NOW

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Read the original post:

Stem Cell Therapy Market Detailed Analysis and Forecast 2017-2025 - 101Newsindustry

Cell Culture Protein Surface Coating Market To Reach USD 659.1 Million By 2026 | Reports And Data – GlobeNewswire

New York, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Increasing interest of biotechnology companies and scientists in cancer and stem cell research, rising commercial production of biologics like proteins, antibodies and vaccines & drugs have boosted the cell culture market because of which cell culture protein surface coating market has also seen a proportional growth.

According to the current analysis of Reports and Data, the global cell culture protein surface coating market was valued at USD 238.3 million in 2018 and is expected to reach USD 659.1 million by the year 2026, at a CAGR of 13.6%. Cell culture is a process in which cells are grown under controlled physical environment outside their natural environment. Cell culture protein surface coating helps to improve adhesion and growth of in vitro cell culture. These cells are helpful in developing model systems for research, studying cellular functions, stem cell research, drug discovery, and genetic engineering. The growing scope of associated culture industry across the globe has helped the market for cell culture protein surface coating grow.

Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/2265

With incidents of chronic diseases on the rise around the world, the research, drug development, and clinical trials on various therapies also need to be increased. Therefore, the demand for target industry usage will also have a boost. This will be a significant factor fuelling the growth of this industry. It also helps in cell isolation, which plays a very vital role in the diagnostics and research of chronic diseases. It helps in drug discovery by studying the behavior of the cells and their response to disease and drugs. This technique of drug discovery helps to generate medicines that can be used for the treatment of various diseases such as cancer, genetic disorders, and autoimmune diseases. All these factors have contributed towards a positive dynamic growth curve of this industry, and it is expected to keep growing in the coming years.

North America is recognized for its healthcare-related culture laboratories and research funding. The National Institutes of Health (NIH) extensively finance stem cell research in the United States each year. Moreover, the National Cancer Institute (NCI) allocates high funding for research into cancer disorders and personalized medicine to institutions and companies working with research centers. These aspects boost the significance of cell culture activities. The healthcare expenditure is, therefore, high in the United States and Canada.

Furthermore, improving government initiatives, availability of research funds from private as well as public bodies, and rising awareness about the benefits of this technology are among the key factors propelling the growth of the target market.

Further key findings from the report suggest

To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/cell-culture-protein-surface-coating-market

Segments covered in the report:

For the purpose of this study, Reports and Data have segmented the cell culture protein surface coating market on the basis of coating type, protein source, end use and region:

Coating Type (Revenue in USD Billion, 2018 - 2026)

Protein Source (Revenue in USD Billion, 2018 - 2026)

Order Now: https://www.reportsanddata.com/checkout-form/2265

Regional Outlook (Revenue in USD Million; 20162026)

Browse more similar reports on Diagnostics category by Reports And Data

Photomedicine Market - https://www.reportsanddata.com/report-detail/photomedicine-market

In-Vitro Diagnostics (IVD) Quality Control Market - https://www.reportsanddata.com/report-detail/in-vitro-diagnostics-ivd-quality-control-market

Point of Care (PoC) Diagnostics Market - https://www.reportsanddata.com/report-detail/point-of-care-poc-diagnostics-market

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help clients make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

See more here:

Cell Culture Protein Surface Coating Market To Reach USD 659.1 Million By 2026 | Reports And Data - GlobeNewswire

Margaret Lawrence ’36, Who Was Rejected From Cornell’s Medical School Because She Was Black, Dies at 105 – Cornell University The Cornell Daily Sun

When Margaret Lawrence 36 arrived in Ithaca in 1932, she was the only black student in her class. Denied on-campus housing due to her race, the future psychoanalyst and pediatrician once slept in an attic, working as a live-in maid to help pay for her Cornell degree.

Lawrence whose name was Margaret Cornelia Morgan at the time applied in her senior year to the medical school to continue her education at Cornell, but was denied, since twenty-five years ago there was a Negro man admitted, a dean explained, and it didnt work out. That student had died from tuberculosis.

The Cornell Daily Sun June 12, 1936

Of this roster of graduates published in 1936, Margaret Lawrence 36 was the only black student.

Columbia University did accept Lawrence, propelling the alumna to eventually direct the Therapeutic Developmental Nursery at Harlem Hospital and becoming chief of the Developmental Psychiatry Service for Infants and Children for 21 years.

When Lawrence who would be known for her empathy for children patients, according to The New York Times was in medical school, she continually faced the compounded difficulty of sexism and racism as one of 10 women, and the only black woman in her class.

At Cornell, Lawrence was a skilled archer, scoring in the top eight and snagging a spot on the archery team, according to archived editions of The Sun.

She would chronicle these challenges in a book titled Balm in Gilead: Journey of a Healer, written by her daughter, Prof. Sara Lawrence-Lightfoot, sociology, Harvard University. In one recollection, Lawrence described how when she turned 21 and went to register to vote, she was asked to take a literacy test.

The Cornell Daily Sun on May 22, 1934

During her time at Cornell, Lawrence was involved in archery, repeatedly scoring among the top.

Lawrences story resonated with former Cornell University President Frank H. T. Rhodes, who reportedly heard her struggles and penned a short apology letter for the discrimination in 2008.

He wrote her a short letter of sincere and serious apology for the assaults ofdiscrimination and racism she had suffered, Lawrence-Lightfoot said.

According to The New York Times, Lawrence-Lightfood said that her mother appreciated the respectful and heartfelt apology.

Lawrence died on Wednesday in Boston at an assisted living center at the age of 105.

See the article here:

Margaret Lawrence '36, Who Was Rejected From Cornell's Medical School Because She Was Black, Dies at 105 - Cornell University The Cornell Daily Sun


...10...1819202122...304050...